Ranolazine and its Antiarrhythmic Actions.

Area of Science:

• Cardiology
• Pharmacology
• Electrophysiology

Background:

• Ranolazine is an FDA-approved antianginal agent.
• Recent findings highlight its antiarrhythmic actions via peak and late sodium current inhibition.

Purpose of the Study:

• To review the mechanisms and clinical data of ranolazine's antiarrhythmic efficacy.
• To explore its potential in suppressing supraventricular and ventricular arrhythmias.

Main Methods:

• Review of experimental and clinical data.
• Analysis of findings from the MERLIN-TIMI 36 trial and other studies.

Main Results:

• Ranolazine shows efficacy in suppressing supraventricular and ventricular arrhythmias, especially in patients with non-ST-segment elevation acute coronary syndrome.
• The drug appears more effective in pathological conditions like heart failure, ischemia, tachyarrhythmias, and long QT3 syndrome.
• Ranolazine may offer antiarrhythmic effects without inducing proarrhythmia.

Conclusions:

• Ranolazine exhibits promising antiarrhythmic properties with a favorable safety profile.
• Larger randomized controlled trials are necessary to further evaluate its antiarrhythmic effects and clinical utility in patients with arrhythmias.